STAT Scooplet: A growing backlash to Pelosi’s arbitration plan
A coalition of industry groups, including BIO and the Council for Affordable Health Coverage, which includes PBMs, drug makers, and insurers, wrote to House and Senate leadership Friday slamming the idea of allowing a government arbiter to decide the price Medicare pays for drugs — a central component of the drug pricing proposal Speaker Nancy Pelosi is working on.
“Taken as a whole, the lack of transparency in the binding arbitration process, combined with the significant (if not total) lack of recourse for participating parties in the event that the process goes awry, creates a scenario that allows for little accountability and begs for abuse,” states the letter, which was shared with STAT.
PhRMA, too, has begun to speak out. “Simply put, patients in Medicare Parts B and D would lose under government arbitration,” PhRMA wrote in a June 10 blog post.
It’s an ironic turn of events, since progressives have chided the speaker for months because they see the reported proposal as too weak on drug makers — so much so that Pelosi has already significantly reworked her as-yet-unveiled plan.
“Taken as a whole, the lack of transparency in the binding arbitration process, combined with the significant (if not total) lack of recourse for participating parties in the event that the process goes awry, creates a scenario that allows for little accountability and begs for abuse,” states the letter, which was shared with STAT.
PhRMA, too, has begun to speak out. “Simply put, patients in Medicare Parts B and D would lose under government arbitration,” PhRMA wrote in a June 10 blog post.
It’s an ironic turn of events, since progressives have chided the speaker for months because they see the reported proposal as too weak on drug makers — so much so that Pelosi has already significantly reworked her as-yet-unveiled plan.
No hay comentarios:
Publicar un comentario